Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models

Dallas B. Flies, Shengdian Wang, Haiying Xu and Lieping Chen

*J Immunol* 2011; 187:1537-1541; Prepublished online 18 July 2011;
doi: 10.4049/jimmunol.1100660
http://www.jimmunol.org/content/187/4/1537

Supplementary Material

http://www.jimmunol.org/content/suppl/2011/07/19/jimmunol.1100660.DC1

References

This article *cites 17 articles*, 6 of which you can access for free at:
http://www.jimmunol.org/content/187/4/1537.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models

Dallas B. Flies,* Shengdian Wang, † Haiying Xu, ‡ and Lieping Chen* §

Upon interaction with B7 homolog 1, programmed death-1 (PD-1) transmits a critical coinhibitory signal to T cells to negatively regulate immune responses. By extensively searching the genomic database with the IgV region of PD-1, we identified a homolog and named it PD-1 homolog (PD-1H). PD-1H is broadly expressed on the cell surface of hematopoietic cells and could be further upregulated on CD4+ and CD8+ T cells following activation. We have generated an mAb against PD-1H, which strikingly prevents acute graft-versus-host disease in semi- and fully allogeneic murine models, leading to full chimerism following treatment. Graft-versus-host disease remains a primary hindrance to successful allogeneic hematopoietic cell transplantation therapy for the treatment of hematologic malignancy. Therefore, manipulation of PD-1H function may provide a new modality for controlling T cell responses to allogeneic tissues in transplant medicine. The Journal of Immunology, 2011, 187: 1537–1541.

The PD-1H sequence presented in this article has been submitted to the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov) under accession number NM_028732.

Materials and Methods

Mice

Six- to 8-wk-old mice were purchased from the National Cancer Institute (Frederick, MD). Mice were housed in specific pathogen-free facilities and treated in accordance with Institutional Animal Care and Use Committee standards at Johns Hopkins (Baltimore, MD) and Yale Universities (New Haven, CT).

Generation of fusion proteins, mAbs, and stable cell transfectants

Full-length mouse PD-1H cDNA for cloning into pcDNA3.1 vector (Invitrogen, Carlsbad, CA) was generated by PCR from total splenocyte cDNA. The mouse (m)PD-1H extracellular domain was fused in-frame to the CH2-CH3 portion of mlgG2a as previously described (13). mPD-1Hg plasmid was stably transfected into Chinese hamster ovary cells, and expression was confirmed by ELISA. PD-1HIg fusion protein was produced and purified as previously described (13). mAbs were generated against mPD-1H by immunization of Armenian hamsters with mPD-1Hg, fused to sp2/0 myeloma cells (American Type Culture Collection, Manassas, VA), and produced as previously described (14).

Received for publication March 10, 2011. Accepted for publication June 17, 2011. This work was partially supported by Grants CA97085 and CA85721 from the National Institutes of Health.

*Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06519; †Department of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; ‡Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; and §Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06519.

Address correspondence and reprint requests to Dr. Lieping Chen, Department of Immunobiology, Yale University School of Medicine, 10 Amistad Street, New Haven, CT 06519. E-mail address: lieping.chen@yale.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: aGVHD, acute graft-versus-host disease; BDF1, C57BL/6 × DBA/2 F1 hybrid; B7-H1, B7 homolog 1; BM, bone marrow; BMDC, bone marrow-derived dendritic cell; BTLA, B and T lymphocyte attenuator; GVHD, graft-versus-host disease; hamlg, hamster Ig; IHC, immunohistochemistry; LN, lymph node; m, mouse; PD-1, programmed death-1; PD-1H, programmed death-1 homolog.

Copyright © 2011 by The American Association of Immunologists, Inc. 0022-1767/11/S16.00
Abs, cell lines, and reagents

Abs against CD4, CD8, Gr-1, CD11b, CD11c, F4/80, DX5, CD19, H-2Kb, H-2Kd, I-A/E, anti-hamster Ig (ham Ig)-biotin, and streptavidin-allophycocyanin were purchased from eBioscience (San Diego, CA). MH5A was biotin-labeled using a PE-O4 biotin-labeling kit from Pierce (Rockford, IL). P815 mastocytoma cell line was purchased from American Type Culture Collection and stably transfected with full-length mPD-1H with Fugene (Roche, Mannheim, Germany) according to protocol.

mRNA expression panels

A mouse multiple-tissue cDNA panel (Mouse MTC Panel I) was purchased from Clontech (Palo Alto, CA). For cell-specific mRNA expression analysis, cells were enriched by MACS beads (Miltenyi Biotec, Auburn, CA), and cDNA was prepared using a SMART PCR cDNA synthesis kit (Clontech).

Immunohistochemistry

Tissues from wild-type C57BL/6 mice 6 wk of age were harvested, placed in formalin fixative, and paraffin embedded. Tissues were deparaffinized and rehydrated prior to Ag retrieval in citrate buffer. Tissues were stained with 5 μg/ml biotin-labeled MH5A or biotin-labeled ham Ig-anti-trinitrophenyl control mAb (eBioscience), followed by incubation with amplification system k1500 (DakoCytomation, Glostrup, Denmark). HRP staining was visualized with 3′,3′-diaminobenzidine (Sigma-Aldrich), and slides were counterstained, cleared, and mounted.

GVHD-CTL models and aGVHD models

In aGVHD models, mice were irradiated using a Gamacell 40 irradiator (Cesium source, 0.5 Gy/min dose rate; Atomic Energy of Canada) 12 h before adoptive transfer. In the semiallogeneic lethal model (12 Gy), C57BL/6 bone marrow (BM) was isolated from femurs and tibias by flushing bones with RPMI 1640 supplemented with 10% Fetalclone III (Hyclone/Thermo Scientific) and penicillin-streptomycin (Roche) and disagggregated through a 100-μm mesh screen (BD Biosciences) with a rubber syrupy plunger. RBCs were lysed in ACK buffer, and T cells were depleted with CD90.2 (thy1.2) MACS beads according to protocol (Miltenyi Biotec). T cells were isolated from total lymph node (LN) cells and enriched using pan T cell MACS negative selection beads according to protocol (Miltenyi Biotec). BM plus T cells were adoptively transferred to B6D2/F1 mice by tail vein injection with 200 μg MH5A or ham Ig. In the fully allogeneic lethal model (9 Gy), BALB/c BM was isolated as above, whereas total LN cells were transferred without selection. Each experiment was performed at least three times with five mice per group.

Software

Sequence analysis was performed using MacVector (MacVector, Cary, NC). Flow cytometry analysis was performed using FlowJo analysis software (Tree Star, Ashland, OR).

Results and Discussion

Identification of PD-1H as a homolog of PD-1 within the CD28 family

PD-1H was initially identified by searching National Center for Biotechnology Information databases for molecules with IgV region similarity to known co-signaling molecules. PD-1H (accession number: NM_028732; http://www.ncbi.nlm.nih.gov; Mouse Genome Informatics symbol: 4632428N05Rik) is a 309-aa (311 aa in human) type I transmembrane protein composed of seven exons (Fig. 1A). The location of this open reading frame is on the forward strand of murine chromosome 10 (location 10qB4) and the reverse strand of human chromosome 10 (location q22.1). This putative protein has 85.6% similarity between mouse and human and contains an N-terminal signal peptide, single IgV domain, transmembrane region, and cytoplasmic tail (Fig. 1B).

The single IgV domain of PD-1H had sequence similarity with both CD28 and B7 family molecules. However, although the PD-1H IgV domain had similarity with the B7-H1 IgV domain (data not shown), full-length PD-1H resembled CD28 family molecules by phylogenetic analysis and appeared related to PD-1 (Fig. 1C). Phylogenetic analysis of mouse and human full-length proteins using the neighbor joining method suggests PD-1H is a distant relative to other CD28 family members, as are PD-1 and BTLA. Alignment of the PD-1H IgV region with CD28 members shows highest identity with PD-1 while having the highest similarity with CD28 (Fig. 1D, 1E). Interestingly, PD-1H and PD-1 share several residues in the IgV domain that are unique only to these two molecules, whereas PD-1H contains a 12-residue segment that does not align with any CD28 family molecules and appears unique in the mammalian proteome, indicating this moiety may confer unique function to PD-1H (Fig. 1E).

PD-1H is broadly expressed in murine tissues and hematopoietic cells

Reminiscent of PD-1, PD-1H mRNA and protein were found to be broadly expressed (Fig. 2A–D). PD-1H mRNA was expressed on most tissues examined including heart, brain, lung, muscle, kidney, testis, and embryo, but was most highly expressed in the spleen (Fig. 2A). Cell-specific mRNA expression showed that PD-1H was expressed in naïve and activated T cells, unstimulated and IFN-γ-stimulated BM-derived dendritic cells (BMDCs), as well as in PMA-activated B cells (Fig. 2B). An mAb (clone MH5A) was generated by immunization with PD-1Hlg, which specifically stained P815 cells transfected with full-length PD-1H plasmid, but not control plasmid, and binding could be blocked by addition of excess PH-H1Hg (Fig. 2C). MH5A specificity was confirmed by ELISA and immunohistochemistry (IHC) (data not shown). IHC staining with MH5A for PD-1H expression in C57BL/6 spleen showed specific staining for PD-1H in both the T cell zone and marginal zone (Fig. 2D). Similarly, LN T cell zones were positive for PD-1H, as well as endothelial cells of the afferent lymphatic sinus and high endothelial venules. Medullary thymic epithelial cells were highly positive for PD-1H, whereas small clusters of unidentified cells staining with a granular cytoplasmic pattern were positive for PD-1H in both the thymus and BM. In the small intestine, T cells in the lamina propria were positive for PD-1H.

Flow cytometric analysis confirmed expression of PD-1H on F4/80+ peritoneal macrophages, mature BMDCs, total BM, CD11b+Gr-1+ neutrophils, and CD4+ and CD8+ T cells (Fig. 2B). NK cells expressed low levels of PD-1H, whereas B cells were negative. Expression of PD-1H on T cells was most potently upregulated by PMA plus ionomycin (Fig. 2D), whereas anti-CD3 alone, anti-CD3 plus anti-CD28, and Con A were also capable of PD-1H induction (data not shown). These data support a broad expression pattern of PD-1H, which is more comparable to BTLA, ICOS ligand, B7-H1, and B7-H4, as opposed to the more restricted expression pattern of CD28, CTLA-4, and ICOS (15).

PD-1H mAb treatment prevents aGVHD

We employed two models of aGVHD to explore the function of PD-1H in immune modulation in vivo. In the first model,
semiallogeneic (partially MHC-mismatched) C57BL/6 (B6, H-2b) naive donor T cells and T cell-depleted BM were adoptively transferred to lethally irradiated C57BL/6 mice (BDF1, H-2bxd) (Fig. 3A). The second aGVHD model examined was a fully allogeneic (completely MHC-mismatched) model in which BALB/c (BALB, H-2d) total LN and BM cells were adoptively transferred to lethally irradiated B6 mice (H-2b) (Fig. 3B). Astonishingly, in both models, a single 200-mg dose of MH5A prevented aGVHD and resulted in nearly complete chimerism by day 30, as indicated by flow cytometry for circulating donor CD11b+Gr1+ neutrophils and donor CD4+ and CD8+ T cells (Fig. 3, insets). Analysis of donor T cells in an aGVHD model after transfer of B6 LN cells to BDF1 mice by flow cytometry showed a profound reduction in accumulation and expansion of both CD8+ and CD4+ T cells in spleens and livers with MH5A treatment (Supplemental Fig. 1A). Additionally, MH5A treatment greatly reduced numbers of infiltrating FIGURE 1. Genomic organization, sequence, and alignment of PD-1H. A. mPD-1H is composed of seven exons: 5′ untranslated region and signal peptide are located in exons 1 and 2; extracellular domain is located in exons 2, 3, and 4; transmembrane domain is in exon 4; intracellular domain is in exons 4, 5, 6, and 7; and 3′ untranslated region is located in exon 7. B. The mouse (top) and human (bottom) full-length PD-1H sequences have 85.6% similarity (shaded). All seven cysteines are conserved between species (yellow). Mouse and human have three conserved N-linked glycosylation sites (blue), whereas human PD-1H has only one. The mouse intracellular domain has three tyrosine residues (blue), whereas the third tyrosine residue in the human protein is mutated to a histidine (red). Mouse and human proteins have two potential conserved protein kinase C docking sites (red). Additionally, mouse and human PD-1H proteins have 15 conserved proline residues (green). C. Phylogenetic analysis of full-length mPD-1H with CD28 family members using a Gonnet similarity matrix and neighbor joining method. D, Matrix of mPD-1H IgV domain identity (white) and identity and similarity (shaded) with members of the CD28 family IgV and IgC domains. E, Alignment of mPD-1H IgV domain with CD28 family member IgV and IgC domains. Similar and identical residues are shaded gray. Conserved cysteines required for IgV β sheet linkage are in yellow (note BTLA has an IgC domain), and conserved tyrosine residues are shaded in orange. Residues that align only for CD28, CTLA-4, and ICOS are in green, whereas residues that align for PD-1H and PD-1 are in blue. Ligand-binding sites for BTLA, CTLA-4, and ICOS are in red, whereas the PD-1 ligand-binding site is in red letters.
T cells in all aGVHD target tissues examined, including spleen, liver, small intestine, lung, and kidney by IHC analysis (Supplemental Fig. 1B). Moreover, visual observation confirmed MH5A-treated mice retained healthy coat sheen and increased mobility, activity, and appetite compared with hamIg-treated controls. Finally, MH5A-treated mice in both models of aGVHD were capable of living up to 18 mo, with no indication of GVHD or other illnesses such as cancer or infection, thus suggesting a fully reconstituted, normal functioning immune system with tolerance to allogeneic Ags.

Our findings are unexpected because few mAbs targeting a single cosignaling molecule are capable of such potent prevention of aGVHD (1). Existing allogeneic transplant therapies typically employ broad pharmacologic immunosuppression or cellular depletion, resulting in immunodeficiency and leading to recurrence of malignancy and infections (16). Therefore, new therapeutic modalities must be developed to specifically inhibit destruction of normal recipient tissues while maintaining overall immune function. During the process of publication, we noticed a recent article by Wang et al. (17) also describes PD-1H as an immune suppressive molecule. Nevertheless, we show for the first time, to our knowledge, that Ab to PD-1H is capable of robustly modulating allogeneic T cell responses accompanied with inhibition of T cell accumulation and expansion in GVHD target organs. Precise mechanisms of PD-1H in the modulation of T cell response, however, remain to be elucidated.

Our preliminary studies using in vitro costimulation assays (with anti-CD3 as a mimic TCR signal) and allogeneic MLR using coated or soluble MH5A did not show significant effects on T cell proliferation (Supplemental Fig. 2A,2B), suggesting that MH5A may not directly inhibit T cell function, but that MH5A may have a possible role in non-T cell function in vivo. Administration of PD-1Hig

**FIGURE 2.** PD-1H expression analysis. A, PD-1H mRNA is broadly expressed by multiple tissue blot. B, PD-1H mRNA is expressed in naive and activated T cells, 6-d unstimulated and IFN-γ-stimulated BMDCs, and PMA-activated B cells. C, MH5A mAb binds P815 cells stably transfected with full-length mouse PD-1H, but not control transfected P185 cells (shaded histogram). Binding of MH5A was competitively inhibited by addition of excess soluble PD-1Hlg. D, Expression of PD-1H on normal tissues by IHC examination of paraffin-embedded C57BL/6 tissues using biotin-labeled MH5A mAb. Original magnification ×10. E, Flow cytometric analysis of PD-1H surface expression. mF4/80+ peritoneal macrophages, circulating CD11b+Gr-1+ neutrophils, and mature 7-d GM-CSF plus IL-4–cultured BMDCs are positive for PD-1H, as are a large percentage of total BM cells. NK cells express low levels of PD-1H, whereas B cells are negative for PD-1H protein expression. Isotype control staining is shaded. Naive CD4+ and CD8+ T cells constitutively express PD-1H (light gray shaded), which could be further upregulated within 2 h when stimulated with PMA plus ionomycin (open histogram). Isotype control for T cell staining shaded in dark gray.

**FIGURE 3.** Anti–PD-1H treatment robustly inhibits aGVHD. A, Lethally irradiated BDF1 mice received 5 × 10^6 T cell-depleted BM plus 3 × 10^6 pan T cells and 200 μg hamIg (open triangles) or MH5A (closed squares) on day 0. Inset, Analysis of chimerism at 30 d by FACS analysis of circulating donor (H-2d–negative) neutrophils (light gray bar), CD4+ T cells (dark gray bar), and CD8+ T cells (black bar). B, Lethally irradiated B6 mice received 5 × 10^6 BM plus 1 × 10^7 total LN cells and 200 μg hamIg (open triangles) or MH5A (closed squares) on day 0. Inset, Analysis of chimerism at 30 d for circulating donor (H-2d–positive) neutrophils (light gray bar), CD4+ T cells (dark gray bar), and CD8+ T cells (black bar).
recombinant fusion protein could also prevent aGVHD, a result similar to the treatment by MH5A (data not shown). This finding implicates a possible antagonistic effect of MH5A in vivo. These findings suggest that PD-1H plays a significant role in immune function and as a result need to be examined in detail for mechanisms of action.

Disclosures
The authors have no financial conflicts of interest.

References